Condition
Pineoblastoma clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Pineoblastoma clinical trials that are recruiting, at sites in 2 countries (most in United States (5), Canada (1)). By phase: Phase 1 (3), Early Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 2Countries
Newest Pineoblastoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| B7-H3 CAR T cells for recurrent brain tumors in kids and young adults | Phase 1 | Boston, Massachusetts and 1 other locations | Recruiting | Feb 5, 2026 |
| GPC2-targeted CAR T cell therapy for relapsed or refractory medulloblastoma in children and young adults | Phase 1 | Palo Alto, California | Recruiting | Jul 25, 2025 |
| TP53 gene therapy (SGT-53) with nivolumab and focused radiation for children with recurrent brain tumors | Early Phase 1 | Washington D.C., District of Columbia | Recruiting | Jun 12, 2025 |
| Intrathecal topotecan with maintenance chemotherapy after consolidation for high‑risk embryonal brain tumors in children under 6 | Early Phase 1 | Calgary, Alberta and 12 other locations | Recruiting | Apr 24, 2025 |
| Immunotherapy using personalized T cells for pediatric brain tumors | Phase 1 | Washington D.C., District of Columbia | Recruiting | Jan 5, 2024 |
| Registry for rare lung tumors and DICER1-related conditions | — | Minneapolis, Minnesota | Recruiting | Dec 22, 2017 |
All recruiting trials (6)
-
B7-H3 CAR T cells for recurrent brain tumors in kids and young adults
This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.
-
GPC2-targeted CAR T cell therapy for relapsed or refractory medulloblastoma in children and young adults
This trial will test whether autologous GPC2-targeted CAR T cells delivered into the brain ventricle are safe and active for children and young adults with relapsed or refractory medulloblastoma or similar CNS embryonal tumors.
-
TP53 gene therapy (SGT-53) with nivolumab and focused radiation for children with recurrent brain tumors
This study tests a TP53 gene therapy called SGT-53 combined with the immune drug nivolumab and focused radiation in children whose brain tumors have come back, grown, or not responded to prior treatment.
-
Intrathecal topotecan with maintenance chemotherapy after consolidation for high‑risk embryonal brain tumors in children under 6
This study will test whether monthly intrathecal topotecan plus a year of oral maintenance chemotherapy after high‑dose consolidation is feasible and tolerable for children under 6 with high‑risk embryonal brain tumors.
-
Immunotherapy using personalized T cells for pediatric brain tumors
This study is testing a new treatment using personalized immune cells to help young children with certain brain tumors that haven't completely gone away after standard treatment.
-
Registry for rare lung tumors and DICER1-related conditions
This study is collecting information about rare lung tumors in children, like pleuropulmonary blastoma, to help doctors understand how these conditions develop and how to treat them better.
Related topics
Quick answers
How many Pineoblastoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (5 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.